Key Points
- Insider sale: Nuvalent insider Deborah Ann Miller sold 14,300 shares on Jan 22 at an average price of $110.16 for $1.575M, cutting her stake by 19.34% to 59,634 shares (≈$6.57M).
- Ongoing insider selling: Miller has repeatedly sold shares since October—including 24,200 on Nov 17 and 21,800 on Oct 30—representing substantial, multi-million‑dollar disposals over recent months.
- Company snapshot: Nuvalent is a clinical‑stage oncology firm (lead programs NVL‑520 and NVL‑655); the stock opened at $106.44, trades in a 1‑year range of $55.53–$113.01, has a market cap of ~$7.74B, and carries a consensus "Moderate Buy" with an average target of $138.33.
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Deborah Ann Miller sold 700 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $109.84, for a total value of $76,888.00. Following the completion of the transaction, the insider owned 59,634 shares of the company's stock, valued at $6,550,198.56. The trade was a 1.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Deborah Ann Miller also recently made the following trade(s):
- On Thursday, January 22nd, Deborah Ann Miller sold 14,300 shares of Nuvalent stock. The shares were sold at an average price of $110.16, for a total value of $1,575,288.00.
- On Tuesday, January 6th, Deborah Ann Miller sold 2,589 shares of Nuvalent stock. The stock was sold at an average price of $97.16, for a total value of $251,547.24.
- On Monday, January 5th, Deborah Ann Miller sold 4,363 shares of Nuvalent stock. The stock was sold at an average price of $97.32, for a total value of $424,607.16.
- On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total transaction of $2,553,100.00.
- On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The stock was sold at an average price of $103.16, for a total transaction of $2,248,888.00.
Nuvalent Price Performance
Shares of NUVL opened at $106.44 on Friday. The firm has a 50-day simple moving average of $105.12 and a two-hundred day simple moving average of $91.07. The stock has a market cap of $7.74 billion, a PE ratio of -20.01 and a beta of 1.32. Nuvalent, Inc. has a 1-year low of $55.53 and a 1-year high of $113.01.
Nuvalent (NASDAQ:NUVL - Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.39) by ($0.31). During the same period in the previous year, the firm earned ($1.28) EPS. As a group, sell-side analysts expect that Nuvalent, Inc. will post -3.86 earnings per share for the current fiscal year.
Institutional Trading of Nuvalent
Several hedge funds have recently added to or reduced their stakes in NUVL. GAMMA Investing LLC lifted its stake in Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company's stock worth $34,000 after acquiring an additional 108 shares during the last quarter. US Bancorp DE raised its holdings in shares of Nuvalent by 10.0% in the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company's stock valued at $179,000 after purchasing an additional 188 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of Nuvalent by 3.7% during the 2nd quarter. Kennedy Capital Management LLC now owns 5,504 shares of the company's stock worth $420,000 after purchasing an additional 196 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Nuvalent by 1.9% during the third quarter. Arizona State Retirement System now owns 11,778 shares of the company's stock worth $1,019,000 after purchasing an additional 220 shares in the last quarter. Finally, Principal Financial Group Inc. increased its holdings in Nuvalent by 7.7% in the third quarter. Principal Financial Group Inc. now owns 3,290 shares of the company's stock valued at $285,000 after buying an additional 234 shares during the last quarter. Institutional investors and hedge funds own 97.26% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on NUVL. Truist Financial set a $140.00 price objective on Nuvalent in a report on Monday, November 24th. UBS Group reaffirmed a "buy" rating on shares of Nuvalent in a research report on Wednesday, December 17th. HC Wainwright boosted their price target on shares of Nuvalent from $130.00 to $155.00 and gave the stock a "buy" rating in a research note on Monday, November 17th. Stifel Nicolaus raised their price objective on shares of Nuvalent from $115.00 to $135.00 and gave the company a "buy" rating in a research note on Monday, November 17th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Nuvalent in a report on Thursday. Fifteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $138.33.
Read Our Latest Analysis on NUVL
Nuvalent Company Profile
(
Get Free Report)
Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.
Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
